martes, 23 de junio de 2026
Researchers identify control switch protein that starves tuberculosis bacteria
https://www.news-medical.net/news/20260623/Researchers-identify-control-switch-protein-that-starves-tuberculosis-bacteria.aspx
A protein that acts as a 'control switch,' preventing Mycobacterium tuberculosis from accessing the energy sources it needs to survive, has been identified by researchers at the University of Surrey. The discovery points to a specific vulnerability in the bacterium that could be targeted by new tuberculosis (TB) treatments.
Artificial intelligence helps breast cancer patients avoid unnecessary chemotherapy
https://www.news-medical.net/news/20260623/Artificial-intelligence-helps-breast-cancer-patients-avoid-unnecessary-chemotherapy.aspx
Research led by RCSI University of Medicine and Health Sciences and University College Dublin (UCD) has identified immune markers that could help doctors more accurately determine which breast cancer patients are unlikely to benefit from chemotherapy, potentially sparing some patients from unnecessary treatment. Chemotherapy is regularly used in the treatment of early-stage, ER+HER2- breast cancer, which accounts for around 70% of all breast cancer diagnoses annually.
Rucaparib Delays Next Lines of Therapy in Ovarian Cancer Christos Evangelou, MSc, PhD June 23, 2026
https://www.medscape.com/viewarticle/rucaparib-delays-next-lines-therapy-ovarian-cancer-2026a1000l58?src=
For patients with advanced ovarian cancer, first-line maintenance therapy with rucaparib delays the need for first and second subsequent therapies by roughly a year at each step, according to new data from the phase 3 ATHENA-MONO trial.
Among...
Why Does the Heart Rarely Develop Cancer? Massimo Sandal, PhD June 23, 2026
https://www.medscape.com/viewarticle/why-does-heart-rarely-develop-cancer-2026a1000l75?src=
The heart is one of the organs least likely to develop cancer, a long-standing biologic puzzle that may now have an explanation. A study published in Science found that the mechanical load generated by the beating heart suppresses tumor cell proliferation through a molecular pathway that alters gene expression, raising the possibility of new therapeutic targets.
Geographic and Income Data Missing From Cancer Trial Reports Edited by Katie Lennon June 23, 2026
https://www.medscape.com/viewarticle/geographic-and-income-data-missing-cancer-trial-reports-2026a1000l4k?src=
Geographic and socioeconomic characteristics are almost never reported in randomized cancer clinical trial publications, with no trials reporting rurality, income, or area-level deprivation among 441 US-based trials published from 2020 to 2025. In contrast, reporting of age and sex was nearly universal. Also, race and ethnicity reporting increased from approximately 62% in 2020 to more than 93% in 2025.
The Force Is With You: How Trust Shapes Cancer Care Joe Kita Healing a Broken Trust June 23, 2026
https://www.medscape.com/viewarticle/force-you-how-trust-shapes-cancer-care-2026a1000l59
The patient was a woman in her mid-40s with metastatic pancreatic cancer. “It was a terrible diagnosis for someone so young,” recalled her oncologist Arturo Loaiza-Bonilla, MD, chief of hematology and oncology at St. Luke’s University Health Network in Bethlehem, Pennsylvania.
Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy Authors: David S. Hong, MD; Theodore W. Laetsch, MD; Jonathan C. Trent, MD, PhD
Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy
Authors: David S. Hong, MD; Theodore W. Laetsch, MD; Jonathan C. Trent, MD, PhD
https://www.medscape.org/viewarticle/navigating-advances-trk-fusion-positive-cancers-2025a1000z5i?page=1&src=mkmcmr_driv_stan_mscpedu_260623-OUS-HONC-navigating-advances-trk-fusion-positive-cancers-2025a1000z5i-cta&uac=148436CN
10 years of SAGER sees progress, but not parity The Lancet Rheumatology ++... ++
10 years of SAGER sees progress, but not parity
The Lancet Rheumatology
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00185-2/fulltext?dgcid=raven_jbs_etoc_email
Jul 2026
Volume 8Number 7e493-e586
https://www.thelancet.com/journals/lanrhe/issue/vol8no7/PIIS2665-9913(26)X2006-9
Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial
Prof Eric F Morand, PhDa Send email to eric.morand@monash.edu ∙ Prof Victoria P Werth, MDb ∙ Prof Joerg Wenzel, MD
Prof Joerg Wenzel, MD
Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00337-6/abstract?dgcid=raven_jbs_etoc_feature_lanrhe
Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial
Wing-Yi Wong, MDa,† ∙ Dewi Rijnenberg, MDa,† ∙ Valentin M D Baloche, PhDa ∙ Sofie L M Blokland, PhDa ∙ Paco M J Welsing, PhDa ∙ Femke Bonte-Mineur, MDc ∙ et al.
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00075-5/abstract?dgcid=raven_jbs_etoc_feature_lanrhe
June Is CAH Awareness Month by CheckRare Staff| Published on: May 31, 2026
June Is CAH Awareness Month
by CheckRare Staff| Published on: May 31, 2026
June is CAH Awareness Month, a time dedicated to increasing understanding of congenital adrenal hyperplasia (CAH) and supporting the individuals and families impacted by this rare genetic condition. CAH affects the adrenal glands and can interfere with the body’s ability to produce essential hormones, including cortisol and aldosterone. While the condition is rare, early diagnosis and ongoing specialized care can make a significant difference in patient outcomes.
https://checkrare.com/june-is-cah-awareness-month/
The Importance of Early Diagnosis in IgA Nephropathy by Madaline Spencer| Published on: Jun 23, 2026
The Importance of Early Diagnosis in IgA Nephropathy
by Madaline Spencer| Published on: Jun 23, 2026
Eric Lai, MD, Nephrologist at the West Coast Kidney Institute, discusses the importance of early diagnosis in IgA nephropathy (IgAN).
https://checkrare.com/the-importance-of-early-diagnosis-in-iga-nephropathy/
Closely watched Pfizer lung cancer drug falls short in clinical trial Expectations had been high that sigvotatug vedotin could replace a widely used chemotherapy
https://www.statnews.com/2026/06/22/pfizer-lung-cancer-sigvotatug-vedotin/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9x5Wdo69XtVtG4W1vdTP7Vhp8FpvWd5O-heCg0Zx4gapNlaozW6V-7-9rf3rrBWSRsNLh3oAs7eGGsO4_WpD_nNh4kWA&_hsmi=425127210&utm_content=425127210&utm_source=hs_email
By Matthew HerperJune 22, 2026
Senior Writer, Medicine, Editorial Director of Events
Pfizer's experimental drug for one the most common forms of lung cancer fell short in a clinical trial, serving a big blow to the company, which had positioned the treatment as a key growth driver.
In the Phase 3 study, the drug, called sigvotatug vedotin, did not lead to a statistically significant improvement in overall survival over a chemotherapy called docetaxel.
Pfizer acquired the therapy when it bought Seagen for $43 billion in 2023.
Ending birthright citizenship could be a public health disaster Health is not something that can be cordoned off by immigration status
https://www.statnews.com/2026/06/23/birthright-citizenship-supreme-court-ruling-public-health/
By Rachel E. FabiJune 23, 2026
Fabi is a public health ethicist at SUNY Upstate Medical University’s Center for Bioethics and Humanities.
Sometime before the end of June, the Supreme Court is expected to deliver its...
A sweeping new AI to detect heart conditions is coming to OpenEvidence Pathway’s FDA-cleared EchoNext AI spots structural heart disease in electrocardiograms
https://www.statnews.com/2026/06/23/pathway-labs-echonext-ai-tool-heart-disease-detection/
By Mario AguilarJune 23, 2026
Health Tech Correspondent
Doctors using OpenEvidence will soon be able to upload an image of an electrocardiogram to get an algorithmic prediction of whether a patient has structural heart disease.
Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? Sources point to a single instance in which experimental therapy retatrutide was provided for ‘compassionate use’
https://www.statnews.com/2026/06/23/eli-lilly-unusual-weight-loss-drug-trial-compassionate-use-retatrutide-trump/
By Lizzy LawrenceJune 23, 2026
FDA Reporter
lunes, 22 de junio de 2026
Maternity deserts aren’t accidents. They’re the result of a design flaw The doctor shortage is only part of the problem. The rest is how we train them
https://www.statnews.com/2026/06/19/maternity-desert-physician-shortage-obstetrics-pregnancy-residency-south-dakota/
By Jocelyn Mitchell-Williams and Vijay RajputJune 19, 2026
Mitchell-Williams is senior associate dean for medical education at Cooper Medical School of Rowan University. Rajput is the chair of the department of medical education at the Dr. Kiran C. Patel College of Allopathic Medicine at Nova Southeastern University.
The real work for making dramatic gains against pancreatic cancer is just beginning AI will be necessary for the next major advances — but not for reasons you might expect, write co-founders of Darwin Health
https://www.statnews.com/2026/06/19/daraxonrasib-pancreatic-cancer-miracle-drug-oncosystems-ai/
By Andrea Califano and Gideon BoskerJune 19, 2026
Califano and Bosker are co-founders of Darwin Health.
I work in a psychiatric ER. I’m watching the system fail people in real time The psychiatric emergency room must serve people who aren’t having psychiatric emergencies
https://www.statnews.com/2026/06/22/psychiatric-er-detox-caregivers-autism-emergency/
By Ashley AndreouJune 22, 2026
Andreou is a third-year psychiatry resident training in New York City.
Definium LSD therapy helped patients with major depression in late-stage trial Data bring drug closer to possible approval as Trump administration prioritizes psychedelics
https://www.statnews.com/2026/06/22/definium-lsd-dt120-major-depression-phase-3-data/
By Elaine ChenJune 22, 2026
National Biotech Reporter
Lessons Learned from our Roundtable with Rare Disease Advocates
https://www.fda.gov/news-events/fda-voices/lessons-learned-our-roundtable-rare-disease-advocates?utm_medium=email&utm_source=govdelivery
There is no substitute for sitting across the table from the people we serve. Recently we had the privilege of joining Acting Commissioner Kyle Diamantas, Acting Chief of Staff Lowell Zeta, and Deputy Commissioner Grace Graham for a roundtable discussion with 15 dedicated rare disease leaders. Hearing directly from patients and family members who navigate these incredibly challenging conditions every day was both grounding and motivating. The conversation reinforced our shared mission and highlighted several key areas where the U.S. Food and Drug Administration must continue to evolve to meet the unique needs of the rare disease community.
Access to Naloxone Can Save a Life During an Opioid Overdose
https://www.fda.gov/consumers/consumer-updates/access-naloxone-can-save-life-during-opioid-overdose?utm_medium=email&utm_source=govdelivery
Naloxone products approved by the U.S. FDA are an important tool to reverse overdose in health care and community settings. That’s one of many reasons the FDA is working to help increase access to naloxone. For example, the FDA recently approved the third OTC naloxone nasal spray to reverse the effects of opioid overdose.
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose?utm_medium=email&utm_source=govdelivery
The Lancet Summit 2nd biennial cancer control in China Mar 18–21, 2027 | Shanghai, China
https://thelancetsummit.com/cancer-control-china/index.html
The Lancet Summit
2nd biennial cancer control in China
Mar 18–21, 2027 | Shanghai, China
We are pleased to announce The Lancet Summit: 2nd biennial cancer control in China, a multi-track cancer control conference taking place in Shanghai, China, in 2027.
The Lancet Summit: 2nd biennial cancer control in China will build on previous successful Summits and conferences on cancer control in Asia hosted by The Lancet, The Lancet Oncology, and other Lancet journals. This edition will be a collaboration between several Lancet journals (including The Lancet Haematology, The Lancet Obstetrics, Gynaecology & Women's Health, The Lancet Medical Imaging & Theranostics, and The Lancet) who have convened and collaborated with a renowned Advisory Board to produce a comprehensive programme and a stellar faculty of speakers.
Over 3 days from Mar 19-21, 2027, our esteemed faculty will tackle the challenges posed by common cancers through the opportunities provided by new technologies, including imaging and AI, in China through a lens of cancer control. We have curated a contemporary programme consisting of three parallel tracks covering haematological cancers, women's cancers, and cancer imaging. The meeting will also feature cross-cutting plenary sessions, of interest to all attendees, and a unique half-day symposium dedicated to AI in cancer research. Finally, we will showcase some of the latest research from across China and beyond in dedicated oral abstract sessions and via poster presentations.
Of interest to all in the field of oncology, including physicians, nurses, pathologists, radiologists, oncologists, surgeons, palliative care specialists, epidemiologists, public health practitioners, researchers, and policy makers, The Lancet Summit offers you a unique opportunity to connect with leading experts, engage with cutting-edge research, and help shape the future of cancer control.
We look forward to seeing you in Shanghai in 2027!
Postpartum haemorrhage
https://www.thelancet.com/series-do/postpartum-haemorrhage?dgcid=raven_jbs_etoc_feature_lancetpph26
Postpartum haemorrhage (PPH) is the leading cause of maternal mortality worldwide, occurring in an estimated 27 million women globally every year and causing about 43 000 maternal deaths. Common causes of PPH are uterine atony, trauma, retained placenta, and coagulopathy, with risk heightened by factors including caesarean birth, anaemia, and inadequate antenatal care. As outlined in this three-paper Series, prevention centres on addressing modifiable risk factors for PPH, reducing unnecessary caesarean sections, and administration of uterotonic prophylaxis. Early diagnosis by objective quantification of blood loss and monitoring of vital signs is crucial. Swift treatment following a standardised bundle, and avoiding delays along the management pathway, saves lives.
Primary cervical screening using a universal offer of human papillomavirus self-testing versus usual care in Aotearoa New Zealand: a cluster-randomised, non-inferiority trial
Primary cervical screening using a universal offer of human papillomavirus self-testing versus usual care in Aotearoa New Zealand: a cluster-randomised, non-inferiority trial
Prof Bev Lawton, FRNZCGPa Send email to bev.lawton@vuw.ac.nz ∙ Melanie Gibson, PhDa ∙ Tania Slater, PhDa ∙ Varsha Parag, MScb ∙ Kendall Stevenson, PhDa ∙ Anna Adcock, PhDa ∙ et al.
https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(25)00201-8/abstract?utm_campaign=infocusalerts-obgyn&utm_medium=email&dgcid=hubspot_email_infocusalerts-obgyn_feature&_hsenc=p2ANqtz-85mq8xhdJwrY5FbDFmr9dcMRA4Rcd3maHtcp6bj_SN1cL-viRQxC32UhMGSGjBY5Ly0agRyEjgTDlI6J5Qusgg_up_mw&_hsmi=424677531&utm_content=424646479&utm_source=hs_email
Transforming the Landscape of Gynaecological Cancer: Advances in Prevention, Precision Surgery, and Innovative Systemic Therapies
https://www.thelancet.com/series-do/gynaecological-cancers-advances?dgcid=hubspot_email_infocusalerts-obgyn_feature_eclinmgyno26&utm_campaign=infocusalerts-obgyn&utm_medium=email&_hsenc=p2ANqtz-9PIJ862JrivBrQlDUbwAbkm_hogZ3sDxaW2OyXOP7pVOHwcPNdkTgpJJtWkzFwdmv1KDjcL5PtjBJtnAB61s4MkQSvEg&_hsmi=424677531&utm_content=424646479&utm_source=hs_email
A three-paper Series examines how new strategies and technologies are transforming gynaecological cancer care, with a focus on prevention, precision surgery, and innovative systemic therapies. Paper 1 explores global efforts toward cervical cancer elimination, including progress in HPV vaccination and screening, alternative vaccine strategies, and WHO screening guidelines. Authors also propose targeted actions to accelerate elimination through innovation and more equitable strategies. Paper 2 discusses how computer-assisted and image-guided technologies are redefining surgical lymph node staging in gynaecological cancers. Paper 3 reviews the rapidly evolving field of antibody-drug conjugates (ADCs) in gynaecological cancers. The authors summarise mechanisms of action and findings from clinical trials, and address safety considerations, predictive biomarkers, and future directions for integrating ADCs into personalized treatment strategies.
Application and implications of new global definitions of obesity: a cross-sectional study of South African women Jasantha Odayara ∙ Mustafa Shuaiba ∙ Jennifer Jaob ∙ Annibale Coisc ∙ Julia H Goedecked,e,f ∙ Jami L Josefsong ∙ et al.
Application and implications of new global definitions of obesity: a cross-sectional study of South African women
Jasantha Odayara ∙ Mustafa Shuaiba ∙ Jennifer Jaob ∙ Annibale Coisc ∙ Julia H Goedecked,e,f ∙ Jami L Josefsong ∙ et al.
https://www.thelancet.com/journals/lanafr/article/PIIS3050-5011(26)00022-2/fulltext?dgcid=hubspot_email_infocusalerts-obgyn_feature&utm_campaign=infocusalerts-obgyn&utm_medium=email&_hsenc=p2ANqtz-9gkFrXkJewclkxn868yAkow1wpTfG48kLjE1hZ-86IKm6FsHJ676znxWZTLih3jdJ6shvO-tczWbv9-lIyo0cbH3MROQ&_hsmi=424677531&utm_content=424646479&utm_source=hs_email
Aortic Hope: connecting hearts one beat at a time 15 June 2026 Written by Carin Anderson, founder and chair of the Board, Aortic Hope
https://rarerevolutionmagazine.com/aortic-hope-connecting-hearts-one-beat-at-a-time/
Written by Carin Anderson, founder and chair of the Board, Aortic Hope
In 2015, I survived an aortic dissection—a rare, sudden and often fatal tear in the inner lining of the aorta, the body’s main artery. There were no warning signs, no prior diagnosis of an aneurysm and no clear symptoms. Life changed in an instant.
Mastocytosis: before, during and after diagnosis 17 June 2026 Written by Emma Bishop, RARE Revolution Insights from
Living with mastocytosis means navigating unpredictable, sometimes life‑threatening reactions alongside chronic pain, fatigue and fear. In April 2026, RARE Revolution hosted our 25th RARE Rev-inar. Sponsored by Blueprint Medicines, a Sanofi company, this discussion sees patient advocate Shawna Hull share her own personal journey with mastocystosis, and physician-scientist Dr Polina Pyatilova discuss the complexities of the disease and how a strong patient-doctor relationship allows for optimal care
https://rarerevolutionmagazine.com/mastocytosis-before-during-and-after-diagnosis/
Dr Polina Pyatilova, a dermatologist and physician–scientist working in Berlin, sets the scene, explaining that mastocytosis is a disease characterised by an excess amount of mast cells in the body, due to a genetic variation, often in the KIT gene. The variation means mast cells keep growing and stay constantly active without trigger. There are two main types of mastocytosis; cutaneous, where mast cells are limited to the skin, and systemic, where mast cells are in the bone marrow and throughout the body, meaning multiple organs, such as the skin, gut and bones can be affected.
Results From a Phase 3 Study of Voxzogo (Vosoritide) in Children With Hypochondroplasia by Madaline Spencer| Published on: Jun 22, 2026
Results From a Phase 3 Study of Voxzogo (Vosoritide) in Children With Hypochondroplasia
by Madaline Spencer| Published on: Jun 22, 2026
Andrew Dauber, MD, Chief of Endocrinology at Children’s National Hospital, discusses results from a phase 3 study of Voxzogo (vosoritide) in children with hypochondroplasia.
https://checkrare.com/results-from-a-phase-3-study-of-voxzogo-vosoritide-in-children-with-hypochondroplasia/
A microglial transition could mean the difference between a healthy brain and Alzheimer’s disease Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity. Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/a-microglial-transition-could-mean-the-difference-between-a-healthy-brain-and-alzheimer-s-disease-17273
Whether or not someone develops Alzheimer’s disease could be the result of a key transition in microglial activity, according to new research published recently in Nature Medicine. Researchers led by Mark Fiers at KU Leuven and Bart De Strooper at the University College London, in collaboration with Muna Therapeutics, found that microglia switch from an early inflammatory response in the presence of amyloid plaques to an antigen-presenting state that coincides with the development of tau tangles.
Transthyretin Amyloid Cardiomyopathy: The Rationale for Silencing and Stabilizing Authors: Marianna Fontana, MD, PhD; Caroline Morbach, MD; Ronald Witteles, MD
https://www.medscape.org/viewarticle/transthyretin-amyloid-cardiomyopathy-rationale-silencing-and-2026a1000emm?page=2&uac=148436CN&src=mkmcmr_driv_il_mscpedu_260621_&subtitle-lang-code=es
Amiloidosis cardiaca por transtiretina:
Fundamentos para el silenciamiento
génico y la estabilización
https://www.medscape.org/viewarticle/transthyretin-amyloid-cardiomyopathy-rationale-silencing-and-2026a1000emm?page=1&uac=148436CN&src=mkmcmr_driv_il_mscpedu_260621_12243870_#transcript-download-es
Navigating Myelofibrosis-Associated Anemia Together: Empowering Collaboration and Communication Authors: Francesco Passamonti, MD
Navigating Myelofibrosis-Associated Anemia Together: Empowering Collaboration and Communication
Authors: Francesco Passamonti, MD
https://www.medscape.org/viewarticle/navigating-myelofibrosis-associated-anemia-together-2026a10007ks?page=1&src=mkmcmr_driv_stan_mscpedu_260621-OUS-HONC-navigating-myelofibrosis-associated-anemia-together-2026a10007ks-cta&uac=148436CN
Birth Factors Linked to Greater Early-Onset CRC Risk Edited by Katie Lennon June 22, 2026
https://www.medscape.com/viewarticle/birth-factors-linked-greater-early-onset-crc-risk-2026a1000kx1
Males have 34% higher risk for early-onset colorectal cancer (EOCRC) than females, while Hispanic individuals have 43% higher risk than non-Hispanic White individuals. Among females specifically, every 500-g increase in birthweight raises EOCRC risk by 10%, and having a father older than 35 years increases the risk by 56%.
Cytoreductive Surgery During TKI Therapy May Extend Survival in EGFR-Mutated Non-Small Cell Lung Cancer Edited by Vineeta Teotia
https://www.medscape.com/viewarticle/cytoreductive-surgery-during-tki-therapy-may-extend-survival-2026a1000ks5
Surgical removal of residual tumour masses during TKI therapy was associated with improved survival in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer Christos Evangelou, MSc, PhD June 22, 2026
https://www.medscape.com/viewarticle/dostarlimab-boosts-long-term-survival-endometrial-cancer-2026a1000kyu
Adding the PD-1 inhibitor dostarlimab to standard chemotherapy provides sustained survival benefits for patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) advanced endometrial cancer, according to updated results from the phase 3 RUBY trial.
Pulmonary Embolism Without Chest Pain in a Man Wolfgang Paik June 22, 2026
https://www.medscape.com/viewarticle/pulmonary-embolism-without-chest-pain-man-2026a1000kww
Pulmonary embolism may present without chest pain and still be associated with markedly elevated cardiac biomarkers and right heart strain. The case also emphasizes the diagnostic value of echocardiography and CT angiography in identifying both the embolic burden and a right atrial thrombus. In hemodynamically stable patients, early anticoagulation may be sufficient to achieve complete thrombus resolution, highlighting the need for prompt recognition and treatment.
Mental health for refugees The Lancet Global Health ++... ++...
Mental health for refugees
The Lancet Global Health
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00136-1/fulltext?dgcid=raven_jbs_etoc_email
Jun 2026
Volume 14Number 6
https://www.thelancet.com/journals/langlo/issue/vol14no6/PIIS2214-109X(26)X2004-6
Understanding sugar-sweetened beverage tax implementation globally: a 34-year, population-based observational study in 183 countries
Lizbeth Moreno Loaeza, PhDa Send email to lizbeth.loaeza_moreno@tufts.edu ∙ Laura Lara-Castor, PhDa,b ∙ Julia R Sharib, MSa ∙ Frederick Cudhea, PhDa ∙ Meng Wang, PhDa ∙ Peizhi Li, PhDa,c ∙ et al.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(26)00093-8/fulltext?dgcid=raven_jbs_etoc_feature_langlo
Schistosomiasis in women and adolescent girls
Executive summary
Female genital schistosomiasis (FGS) is a chronic genital disease caused by the deposition of Schistosoma haematobium eggs, affecting at least 40 million women and girls worldwide, primarily in sub-Saharan Africa. Women and girls living with FGS face numerous intersecting challenges and health complications, ultimately contributing to urogenital dysfunction and adverse sexual and reproductive health outcomes.
In this four-paper Series, we examine sex-specific aspects of Schistosoma infections in women and girls, diagnostic techniques and treatment strategies, barriers to diagnosis and treatment, management during pregnancy and implications for offspring, and the interactions with other genital infections and their clinical implications.
https://www.thelancet.com/series-do/schistosomiasis-in-women-and-adolescent-girls?dgcid=raven_jbs_etoc_feature_schistosomiasis26_langlo
domingo, 21 de junio de 2026
Medscape Now! Breast Cancer in the 2020s: Rising Rates, Stalling Mortality, Demographic Disparities Authors: Naseem Bazargan, MPH
https://www.medscape.org/viewarticle/medscape-now-breast-cancer-2020s-rising-rates-stalling-2026a1000i59?page=1
Breast cancer incidence in the United States has been on an upward trajectory since the mid-2000s; in 2026, breast cancer accounted for nearly one-third of all cancer diagnoses among US women.[1] The burden of this trend, however, is not shared equally across demographic groups.[1-4]
Over the decade from 2013 to 2022, breast cancer incidence increased by 1%/y overall, largely driven by localized-stage and hormone receptor--positive diagnoses, with the rise steeper in women aged younger than 50 years (1.4% annually) compared with 0.7%/y in women aged 50 years and older.[1,2] Between 2010 and 2019, increases in breast cancer incidence were observed across all age groups except women aged 60 to 69 years, with the highest annual percentage change (APC; 1.85% [95% CI: 0.96%, 2.77%]) among individuals aged 15 to 29 years (Figure 1)
sábado, 20 de junio de 2026
Why Heat Kills Your Appetite By Ivanhoe Broadcast News on June 26, 2026
Orlando, Fla. (Ivanhoe Newswire) — The temp is starting to go up and that means your body has to work harder to keep cool and that can change how much you want to eat. Experts say digesting food actually raises body temperature, which is why many people naturally feel less hungry in hot weather. At the same time, we can lose up to two quarts of fluid an hour through sweat in extreme heat.
https://www.ivanhoe.com/?p=37239&preview=1&_ppp=58a5e153e9
Starting Smarter: Dating After 50 By Ivanhoe Broadcast News on June 25, 2026
Orlando, Fla. (Ivanhoe Newswire) — June is known as wedding season, a time when love is front and center. But for millions of Americans, they’re still looking for their plus-one. More than 37 million Americans over 50 are single and many are still open to finding love. But here’s the twist, experts say dating later in life isn’t about starting over it’s about starting smarter.
https://www.ivanhoe.com/?p=37235&preview=1&_ppp=907e3f4385
Mid-Year, Mid-Career Panic: Don’t Quit — Reset! By Ivanhoe Broadcast News on June 24, 2026
Orlando, Fla. (Ivanhoe Newswire) — New data shows millions of Americans continue to change jobs each month, with more than three million people quitting their jobs in a typical month last year. And experts say mid-year, right around June, can be a turning point, when people take a hard look at their goals and start thinking about what’s next. And for many, especially in their 40s, it’s not just about a new job. It’s a moment of re-evaluation sometimes called a mid-career panic.
https://www.ivanhoe.com/?p=37233&preview=1&_ppp=6ae3936a78
Banished Words: Are You “Cooked?” By Ivanhoe Broadcast News on June 23, 2026
Orlando, Fla. (Ivanhoe Newswire) — For half a century people have been sounding off about the words they’re sick of hearing. every year, Lake Superior State University releases its “banished words” list, a collection of words and phrases people say are overused, misused or just plain annoying. It’s all in good fun but it also shows how fast language evolves and how quickly we get tired of it.
https://www.ivanhoe.com/?p=37230&preview=1&_ppp=3a258313c9
The Yoga Effect: The Science-Backed Benefits By Ivanhoe Broadcast News on June 22, 2026
Orlando, Fla. (Ivanhoe Newswire) — June 21st marks the International Day of Yoga, a practice that started thousands of years ago in ancient India and today, it’s not just about stretching or relaxing. Researchers are now finding yoga may help everything from chronic pain to mental health, to heart function.
https://www.ivanhoe.com/?p=37227&preview=1&_ppp=ecd292db33
Researchers discover single-cell brain activity that underlies human speech With neuronal data, AI models predicted grammar, meaning, and context of spoken sentences.
Researchers discover single-cell brain activity that underlies human speech
With neuronal data, AI models predicted grammar, meaning, and context of spoken sentences.
By applying machine-learning models to single-cell brain recordings taken from humans in conversation, a National Institutes of Health (NIH)-funded research team identified both individual and collective neuronal activity that reflected key features of language. The work offers unprecedented insight into how neurons encode linguistic information, suggesting that brain activity may one day be used to infer speech-related thoughts, which could be transformative for some patients.
https://www.nih.gov/news-events/news-releases/researchers-discover-single-cell-brain-activity-underlies-human-speech
Characterization of two novel lytic bacteriophages for Klebsiella pneumoniae: molecular studies Bruna R. Guerrero, Stephen C. Emencheta, Carlos A. Quinde, Basilio Cieza, Aakash Basu, Safia Samir, Anthony A. Attama, Ebele B. Onuigbo, Marta M. D. C. Vila, Victor M. Balcão
https://www.academia.edu/journals/academia-molecular-biology-and-genomics/articles?source=journal-top-nav
Metatranscriptomic analyses of SARS-CoV-2 and humans reveal distinct differentially expressed genes
Aditi Nag [1,†]ORCID iD, Athulya Varma [2,†], Ekta Meena [1], Sarita Vatwani [1], Somesh Kumar [3,†]ORCID iD, G. Vinay C. V. Sagar [4,†], P. V. Janardhan Reddy [4,†], P. Hima Kumari [5], Keshav K. Singh [6], S. Anil Kumar [7], Krishna Mohan Medicherla [8]ORCID iD, Rathnagiri Polavarapu [4], Akhilendra B. Gupta [9]ORCID iD, Bipin G. Nair [10], R. Shyama Prasad Rao [11], P. B. Kavi Kishor [12], Gyaneshwer Chaubey* [13]ORCID iD, Sunil Kumar Polipalli [2,3]ORCID iD, Sudipti Arora* [1]ORCID iD, Prashanth Suravajhala* [14]
https://www.academia.edu/3064-9765/3/2/10.20935/AcadMolBioGen8271
A dynamic graph-based PU-learning approach for sequential recommendation in rare disease detection Guanhao Wei* [1] , Yunlong Wang [1] , Li Zhou [1]
https://www.academia.edu/3071-0286/2/2/10.20935/AcadAI8326
Introduction: Rare diseases affect over 300 million people globally; their low prevalence often leads to high misdiagnosis rates. While Electronic Health Record (EHR) data offers opportunities for early detection, existing predictive models struggle to capture the complex, time-sensitive sequence of patient journeys.
https://www.academia.edu/journals/academia-ai-and-applications/articles?source=journal-top-nav
Why cough trial endpoints may be failing promising drugs As a new wave of chronic cough therapeutics enters clinical development, researchers are questioning whether the tools used to measure treatment effects are up to the task. Written byAndrea Corona
Why cough trial endpoints may be failing promising drugs
As a new wave of chronic cough therapeutics enters clinical development, researchers are questioning whether the tools used to measure treatment effects are up to the task.
Written byAndrea Corona
Chronic cough affects an estimated five to ten percent of adults in the US, and for years there has been no FDA-approved treatment for the condition. Despite billions invested in drug development, promising candidates have stumbled at the regulatory finish line — and some researchers argue that how trials measure cough may be as much a factor as the drugs themselves.
https://www.drugdiscoverynews.com/why-cough-trial-endpoints-may-be-failing-promising-drugs-17269
Weekly Rundown: uniQure will seek approval for Huntington's disease gene therapy after switchup at FDA
Weekly Rundown: uniQure will seek approval for Huntington's disease gene therapy after switchup at FDA
Gene therapies dominated the news this week, with positive results for both a CRISPR and non-viral therapy, and a U-turn decision from the FDA.
Written byDDN editorial team
https://www.drugdiscoverynews.com/weekly-rundown-uniqure-will-seek-approval-for-huntington-s-disease-gene-therapy-after-switchup-at-fda-17271
uniQure will seek approval for Huntington’s disease gene therapy after switchup at FDA
uniQure announced that they will move forward with submitting a Biologics License Application (BLA) to the FDA for their gene therapy to treat Huntington’s disease. The news follows the FDA’s prior rejection of their data package back in March, which a former top FDA official called “truly evil.” The decision was part of a string of rejections under former FDA Director of the Center for Biologics Evaluation and Research, Vinay Prasad. After Prasad left the FDA for a second time in April and FDA Commissioner Martin Makary’s exit in May, FDA officials met with uniQure and said that they will now accept a three-year analysis from their Phase 1/2 trial as the primary basis for their BLA. That trial showed that their one-time gene therapy led to a 75 percent slowing of disease at 36 months at the higher dose. UniQure’s stock rose 70 percent after the announcement in anticipation of the possible upcoming FDA approval. “The consistency and strength of the clinical data generated to date give us great confidence in the product's potential to make a meaningful difference for patients,” said Matt Kapusta, CEO at uniQure. – Allison Whitten
Colorectal Cancer Continues to Rise in Younger Adults Mythili Menon Pathiyil, MD
https://www.medscape.com/viewarticle/colorectal-cancer-continues-rise-younger-adults-2026a1000jqm?ecd=wnl_edit_tpal_etid8439165&uac=148436CN&impID=8439165
To give a little background, colorectal cancer, that’s cancer of the colon or rectum, was traditionally considered a disease of older adults. Over the past couple of decades, we’ve been seeing more cases and deaths in younger people under the age of 50. In fact, according to the American Cancer Society, colorectal cancer is currently the leading cause of cancer-related mortality in individuals below the age of 50 in the United States, and this is a drastic shift from prior generations; and it’s concerning because these individuals are not routinely screened.
Are GLP-1s Increasing Eating Disorder Risk? Kathleen Doheny June 18, 2026
https://www.medscape.com/viewarticle/are-glp-1s-increasing-eating-disorder-risk-2026a1000koq?ecd=wnl_edit_tpal_etid8439165&uac=148436CN&impID=8439165
In an era of increasingly easy access to GLP-1s, some experts are raising concerns about the potential for misuse, especially among patients with eating disorders.
Lenalidomide Plus Rituximab for Previously Untreated Advanced Follicular Lymphoma: The 10-Year RELEVANCE Trial Analysis
Lenalidomide Plus Rituximab for Previously Untreated Advanced Follicular Lymphoma: The 10-Year RELEVANCE Trial Analysis
Authors: Nicolas Gower, MD; Pierre Feugier, MD; Jason Westin, MD; Jean-Marc Schiano De Colella, MD; Hervé Tilly, MD; M. Lia Palomba, MD; Edith Julia, MD; Gandhi-Laurent Damaj, MD, PhD; Amandine Durand, MD; Ian Flinn, MD; François Lemonnier, MD, PhD; Nadine Morineau, MD; Loic Ysebaert, MD, PhD; Nancy Bartlett, MD; Catherine Thieblemont, MD; Vincent Ribrag, MD; Thomas Gastinne, MD; Arthur Dony, MD; Ludovic Fouillet, MD; Stephanie Guidez, MD; Roch Houot, MD, PhD; Maria Gomes Da Silva, MD; Jeffrey Barnes, MD, PhD; Fontanet Bijou, MD; Guillaume Cartron, MD, PhD; Alejandro Martin Garcia-Sancho, MD, PhD; Herbert Eradat, MD; Morgane Cheminant, MD, PhD; Armando Lopez Guillermo, MD; Pau Abrisqueta, MD; Julie Abraham, MD; Clémentine Sarkozy, MD, PhD; Koji Izutsu, MD; Gilles Crochet, MD; Laurie H. Sehn, MD, MPH; Argyrios Gkasiamis, MD; Marie Laurence Yge; Loic Chartier; Nathan Fowler; Luc Xerri, MD; Gilles Salles, MD; Franck Morschhauser, MD, PhD
https://www.medscape.org/viewarticle/lenalidomide-plus-rituximab-advanced-follicular-lymphoma-2026a1000jid?page=1&src=wnl_tpal_260619_mscpedu&uac=148436CN&impID=8438174
In the multinational, phase 3 RELEVANCE trial, 1030 patients with previously untreated follicular lymphoma were randomized to receive rituximab + lenalidomide (R2; n = 513) or rituximab-based immunochemotherapy (R-Chemo; n = 517). In the final analysis, at 120 months of follow-up, median progression-free survival (PFS) was comparable between the treatment groups: 110.6 months with R2 vs 102.8 months with R-Chemo, according to the independent review committee assessment. The 10-year PFS rates were 46.4% for R2 and 46.6% for R-chemo. Median overall survival (OS) and time-to-next lymphoma treatment (TTNLT) were not reached in either arm; 10-year OS rates were 82.4% for R2 and 81.1% for R-chemo, and 10-year TTNLT rates were 62.2% for R2 and 66.3% for R-chemo. Overall, patients with progression of disease within 24 months (POD24) had a poorer prognosis than those without POD24 (hazard ratio, 6.215; P <.0001); however, no difference was observed between the study groups. The incidence of second primary malignancies (SPMs) was 2.11 cases per 100 patient-years (95% confidence interval, 1.80-2.46). Only 9 transformations occurred after 24 months (3 with R2 vs 6 with R-chemo). In each study group, 87 patients died, mainly because of lymphoma progression and SPMs. This long-term follow-up of RELEVANCE confirmed that R2 provides a chemotherapy-free alternative to immunochemotherapy in this patient population. This trial was registered at www.clinicaltrials.gov as NCT01476787 and NCT01650701 and at EudraCT as 2011-002792-42.
Arginine Vasopressin Deficiency (AVP-D) Overview by CheckRare Staff| Published on: Jun 2, 2026
Arginine Vasopressin Deficiency (AVP-D) Overview
by CheckRare Staff| Published on: Jun 2, 2026
Christopher Romero, MD, a pediatric endocrinologist at Mount Sinai Medical Center, New York City, and Associate Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai discusses arginine vasopressin deficiency. The name of the rare disease central diabetes insipidus was changed in 2024 to better reflect its etiology.
https://checkrare.com/overview-of-arginine-vasopressin-deficiency/
A brief critique of excitotoxicity in amyotrophic lateral sclerosis Lorenzo Odierna Volume 4, Issue 2 Special Issue: Neurobiological Advances in Neurodegenerative Disorders +... +
https://www.academia.edu/journals/academia-biology/articles?source=journal-top-nav
The excitotoxicity hypothesis has been significantly influential in amyotrophic lateral sclerosis (ALS) research for over thirty years but has seen limited clinical success. Here, the evidence supporting excitotoxicity in ALS is re-examined from first principles, motivated by a critical question: What if excitotoxicity does not underlie ALS pathogenesis? Rather than presenting a definitive answer, this article aims to foster critical discourse by systematically investigating core assumptions and proposing a competing hypothesis grounded in fundamental cellular neurophysiology. The goal of this article is to stimulate open academic dialog, encourage consideration of alternative mechanisms, and inspire investigations that may yield greater insight into ALS pathobiology.
https://www.academia.edu/2837-4010/4/2/10.20935/AcadBiol8371
“Living well”: life with Sjögren’s disease 20 June 2026
https://rarerevolutionmagazine.com/digitalspotlight/living-well-life-with-sjogrens-disease/
When Ana Vieira started experiencing unexplained symptoms as a teenager, she had nothing but an ever-growing sense that something was wrong. It would take two decades before she received a diagnosis of Sjögren’s disease, and another decade before she accessed specialist care that truly recognised the complexity of her condition. Today, Ana is a leading patient advocate, co‑founder and vice president of Sjögren Europe, and an experienced patient research partner at European level
Written by Nicola Miller, RARE Revolution
Interview with Ana Vieira, co-founder and vice president, Sjögren Europe
viernes, 19 de junio de 2026
The best foods for brain health may change as you age
https://www.news-medical.net/news/20260603/The-best-foods-for-brain-health-may-change-as-you-age.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_4_june_2026
From eggs and fish to berries, nuts, and leafy greens, researchers examined how everyday foods may influence brain development, memory, and cognitive aging, and found promising links alongside important gaps in the evidence.
Scientists have recently conducted a structured narrative review of existing evidence to examine how selected animal- and plant-sourced foods may influence neurodevelopment and cognitive performance from early development through older adulthood. This review is available in Nutrients.
How common spices may improve gut, brain, and metabolic health
https://www.news-medical.net/news/20260528/How-common-spices-may-improve-gut-brain-and-metabolic-health.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_4_june_2026
From cinnamon and turmeric to black pepper and oregano, researchers say common kitchen spices may do far more than add flavor, potentially influencing blood sugar, inflammation, brain function, and even the gut microbiome.
Researchers reviewed available literature, particularly studies conducted at the University of California–Los Angeles (UCLA) Center for Human Nutrition, to examine the effects of spices and herbs on human health. This review is available in Nutrition Reviews.
Why new Alzheimer’s drugs are dividing regulators worldwide
https://www.news-medical.net/news/20260531/Why-new-Alzheimere28099s-drugs-are-dividing-regulators-worldwide.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=alzheimer_s_disease_newsletter_4_june_2026
New Alzheimer’s drugs are raising hopes, but modest benefits, ARIA safety risks, high costs, and regulatory disagreements show how uncertain the path to meaningful treatment remains.
A recent World Report published in The Lancet examines the evolving therapeutic landscape and regulatory hurdles surrounding Alzheimer’s disease (AD). Regulators debate whether the clinical benefits of new drugs outweigh their safety concerns and whether those benefits can translate into meaningful patient outcomes. This has led to conflicting approval decisions across countries. Scientists are now developing safer drugs that target broader disease mechanisms and testing them in people at high risk for AD before symptoms appear. Such efforts could advance precision medicine and help reduce the global burden of AD.
How the brain builds sentences, neuron by neuron Neural maps reveal the specialized cells that produce speech. By Max Kozlov
https://www.nature.com/articles/d41586-026-01922-w
In the fraction of a second before a person speaks, their brain weaves together complex grammar, precise vocabulary and the underlying meaning of the language. Now, researchers have tracked the electrical crackle of individual brain cells in real time during unscripted conversations, capturing how sentences are built before a single word is spoken.
Is AI ruining our skills? Early results are in — and they’re not good Reliance on artificial-intelligence tools degrades the abilities of physicians and software engineers, studies show. By Mariana Lenharo
https://www.nature.com/articles/d41586-026-01947-1
As more professionals begin to rely on artificial-intelligence tools in their work, could their hard-earned skills atrophy?
That possibility is a growing concern for medical specialists, computer scientists and other workers. Seventy per cent of nurses and 77% of physicians, for example, are worried about losing their skills because of over-reliance on AI systems, according to a survey of US health-care workers published earlier this month1.
Stem cells banish severe autoimmune disease for 15 years Two people were the first to receive the therapy for a condition that damages the spinal cord and optic nerve. By Rachel Fieldhouse
https://www.nature.com/articles/d41586-026-01925-7
A man and a woman with a rare and devastating autoimmune disease have been in remission for more than 15 years after receiving a stem-cell transplant1. The positive results, which were reported in Med, suggest that the experimental treatment warrants a larger clinical trial, say scientists.
Next-Generation CRISPR Tools Transform Gene Editing And Gene Therapy
https://www.news-medical.net/life-sciences/Next-Generation-CRISPR-Tools-Transform-Gene-Editing-And-Gene-Therapy.aspx
Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA break repair pathways. Advances in base editing, prime editing, epigenome modulation, programmable DNA integration, and targeted delivery systems are bringing safer, more versatile, and clinically scalable genetic medicines closer to routine therapeutic use.
Higher BMI raises risk for 19 cancers as global review expands the obesity-cancer link
https://www.news-medical.net/news/20260617/Higher-BMI-raises-risk-for-19-cancers-as-global-review-expands-the-obesity-cancer-link.aspx
A sweeping analysis of 1.5 million cancer cases shows that excess body weight may shape cancer risk more broadly than previously recognized, with risks varying by cancer type, sex, and region.
In a recent systematic review and meta-analysis published in the journal Nature Metabolism, researchers synthesized decades of peer-reviewed literature to re-evaluate the global relationship between body mass index (BMI) and cancer risk.
Viewpoint: ‘Industrial food’ primer—Challenging the dangerous delusions of the alternative food movement Alex Smith | June 17, 2026
https://geneticliteracyproject.org/2026/06/17/viewpoint-industrial-food-primer-challenging-the-dangerous-delusions-of-the-alternative-food-movement/
Eat real food. It’s the closest thing American alternative food politics has to a creed, and for the better part of two decades it belonged to the left. To eat real food was to opt out of industrial agriculture, to refuse the long ingredient list and the seed oils and the corn-fed beef, and in doing so, to register a quiet protest against the system that produced them. It was, we were told, a progressive politics—an alliance of small farmers, conscientious eaters, and environmentalists against the depredations of Big Ag.
Facts & Fallacies Podcast: The truth about vitamin K shots Cameron English, Liza Lockwood | June 17, 2026
https://geneticliteracyproject.org/2026/06/17/facts-fallacies-podcast-the-truth-about-vitamin-k-shots/
Social media has been awash in panic as one influencer after another wrongly warns prospective parents against the routine (and sometimes life-saving) vitamin K shot, given to newborns right after birth. Claims linking it to pediatric cancer, eczema and other serious conditions are spreading rapidly online, leaving many new moms and dads alarmed and confused.
Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Ocular Myasthenia Gravis by Madaline Spencer| Published on: Jun 16, 2026
Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Ocular Myasthenia Gravis
by Madaline Spencer| Published on: Jun 16, 2026
Carolina Barnett-Tapia, MD, Neuromuscular Neurologist and the University of Toronto, discusses the safety and efficacy of subcutaneous efgartigimod PH20 in ocular myasthenia gravis (oMG).
https://checkrare.com/safety-and-efficacy-of-subcutaneous-efgartigimod-ph20-in-ocular-myasthenia-gravis/
Results From the Phase 3 ElevAATe Clinical Trial in Alpha-1 Antitrypsin Deficiency by Madaline Spencer| Published on: Jun 19, 2026
Results From the Phase 3 ElevAATe Clinical Trial in Alpha-1 Antitrypsin Deficiency
by Madaline Spencer| Published on: Jun 19, 2026
Alaa Hamed, MD, Global Head of Medical Affairs Rare Diseases at Sanofi, discusses results from the phase 2 ElevAATe clinical trial of efdoralprin alfa in patients with alpha-1 antitrypsin deficiency (AATD).
https://checkrare.com/results-from-the-phase-3-elevaate-clinical-trial-in-alpha-1-antitrypsin-deficiency/
Prospective Cutaneous Lymphoma International Prognostic Index Study by CheckRare Staff| Published on: Jun 8, 2026
Prospective Cutaneous Lymphoma International Prognostic Index Study
by CheckRare Staff| Published on: Jun 8, 2026
Julia Scarisbrick, MD, MBhons, ChB, FRCP, is one of the leaders of the PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) study, a registry of patients with cutaneous T-cell lymphoma (CTCL). Dr. Scarisbrick, Professor of Dermatology, Department of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom, discussed the study’s objectives, as well as challenges in the diagnosis of CTCL.
https://checkrare.com/prospective-cutaneous-lymphoma-international-prognostic-index-study/
Can Chemoradiation Improve Outcomes in Pancreatic Cancer? Edited by Victoria Stern June 19, 2026 ++++
Can Chemoradiation Improve Outcomes in Pancreatic Cancer?
Edited by Victoria Stern
https://www.medscape.com/viewarticle/can-chemoradiation-improve-outcomes-pancreatic-cancer-2026a1000krz
June 19, 2026
Adding fluoropyrimidine-sensitized radiotherapy (CXRT) to adjuvant gemcitabine chemotherapy was not associated with improved overall survival or higher rates of grade 4/5 adverse events among patients with resected pancreatic head adenocarcinoma assessed in a phase 3 trial. However, in patients with node-negative disease, adding CXRT to chemotherapy was associated with significant improvements in both overall survival and disease-free survival.
Timely ‘Nudges’ Help Spur Talks on Patient Care Goals
Megan Brooks
https://www.medscape.com/viewarticle/timely-nudges-help-spur-talks-patient-care-goals-2026a1000krj
June 19, 2026
Well-timed prompts directed at oncologists and patients with advanced cancer can encourage discussions about care goals — though they may not be enough to spur those conversations in most cases, a new clinical trial finds.
Reducing Keratinocyte Carcinoma Risk
Kate Johnson
https://www.medscape.com/viewarticle/oral-nicotinamide-cost-effective-reducing-keratinocyte-2026a1000kpq
June 19, 2026
Oral nicotinamide was cost-effective for reducing keratinocyte carcinoma (KC) risk in US veterans with a history of the disease, according to an economic analysis of Veterans Health Administration (VHA) data.
New Immune Therapy Boosts Disease Control in Prostate Cancer
Frederik Joelving
https://www.medscape.com/viewarticle/new-immune-therapy-boosts-disease-control-prostate-cancer-2026a1000kmn
June 18, 2026
Adding an experimental immunotherapy to radiation treatment may extend disease-free survival in men with localized intermediate- or high-risk prostate cancer, according to a phase 3 trial.
MRI Predicts Survival Better Than Histopathology in Rectal Cancer Edited by Mamta Pawara ++++
https://www.medscape.com/viewarticle/mri-predicts-survival-better-than-histopathology-rectal-2026a1000kgu
MRI-detected extramural venous invasion (mrEMVI) in patients with rectal cancer was associated with a more than fivefold increased risk for recurrence and a more than threefold increased risk for death; however, postoperative histopathologically detected EMVI (pEMVI) showed no significant prognostic value in a prospective single-centre cohort.
The HPV Vaccine at 20: Progress Made, Challenges Ahead
Cristina Ferrario
https://www.medscape.com/viewarticle/hpv-vaccine-20-progress-made-challenges-ahead-2026a1000ksf
June 19, 2026
Twenty years ago, a major milestone in cancer prevention was reached when the US. The FDA approved the first human papillomavirus (HPV) vaccine. Introduced in 2006, the quadrivalent vaccine protected against HPV types 16 and 18, which are responsible for most HPV-related cancers, as well as HPV types 6 and 11, which cause genital warts but have low oncogenic potential.
Patients With Breast Cancer Taking GLP-1s Had Better Survival
Sharon Worcester
https://www.medscape.com/viewarticle/patients-breast-cancer-taking-glp-1s-had-better-survival-2026a1000kqq
June 19, 2026
Once again, a large observational study suggests GLP-1 drugs confer an all-cause mortality benefit among patients with cancer.
The study, comparing GLP-1 use vs nonuse in more than 137,000 patients with breast cancer, showed a significant 4% increase in overall survival (OS) in those taking a GLP-1 drug.
Nonconventional B-Cell Depletion Strategies Offer Potential Immune Reset in Refractory Autoimmune Disease
Manuela Callari
https://www.medscape.com/viewarticle/nonconventional-b-cell-depletion-strategies-offer-potential-2026a1000kld
LONDON — Complete eradication of pathogenic B cells and plasma cells within deep tissue niches could offer an “immune reset” for patients with highly refractory, severe autoimmune diseases, according to clinical data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Annual Meeting.
Sober Truth on Preventing Underage Drinking (STOP) Act Tuesday, June 23, 2 p.m. ET +++++ +
Sober Truth on Preventing Underage Drinking (STOP) Act
Tuesday, June 23, 2 p.m. ET
https://events.gcc.teams.microsoft.com/event/6db900fd-2913-4d56-a39a-0a77e02ad99c@d58addea-5053-4a80-8499-ba4d944910df?utm_source=SAMHSA&utm_campaign=01baab3590-EMAIL_CAMPAIGN_2026_06_18_06_40&utm_medium=email&utm_term=0_-01baab3590-167840245
The purpose of this program is to prevent and reduce alcohol use among youth and young adults ages 12 to 20 in communities throughout the United States.
You are invited to participate in an informational webinar for organizations interested in applying for the upcoming Sober Truth on Preventing Underage Drinking (STOP) Act Grants Notice of Funding Opportunity.
Building Communities of Recovery (BCOR)
Tuesday, June 23, 2 p.m. ET
The purpose of this program is to support organizations in mobilizing and connecting community resources to increase access to long-term recovery support for people with substance use disorders and co-occurring substance use and mental disorders.
https://events.gcc.teams.microsoft.com/event/493c4456-4b64-4e29-8f6e-b199f8bfe771@d58addea-5053-4a80-8499-ba4d944910df?utm_source=SAMHSA&utm_campaign=01baab3590-EMAIL_CAMPAIGN_2026_06_18_06_40&utm_medium=email&utm_term=0_-01baab3590-167840245
Tribal Behavioral Health: Suicide Prevention
Tuesday, June 23, 2:30 p.m. ET
The purpose of this program is to prevent and reduce suicide, suicide attempts, and deaths by suicide among American Indian/Alaska Native (AI/AN) youth and young adults through age 24 in Tribal communities. With this program, SAMHSA aims to reduce the impact of suicidal ideation, suicide attempts, and deaths from suicide through community-wide suicide prevention activities that incorporate Indigenous knowledge and healing methods that reduce risk and support wellness.
https://events.gcc.teams.microsoft.com/event/d295da3d-a4be-4d10-a1bc-bc430a9c2510@d58addea-5053-4a80-8499-ba4d944910df?utm_source=SAMHSA&utm_campaign=01baab3590-EMAIL_CAMPAIGN_2026_06_18_06_40&utm_medium=email&utm_term=0_-01baab3590-167840245
Strategic Prevention Framework - Partnerships for Success for States (SPF-PFS States)
Wednesday, June 24, 2 p.m. ET
The purpose of the SPF-PFS States grant program is to help prevent and reduce the initiation and progression of substance use and its related problems. The program intends to build prevention capacity throughout states and to strengthen the capacity of local community prevention providers to implement evidence-based and evidence-informed prevention strategies.
https://events.gcc.teams.microsoft.com/event/a1d81f2f-3962-4c38-b649-cf7f02011eca@d58addea-5053-4a80-8499-ba4d944910df?utm_source=SAMHSA&utm_campaign=01baab3590-EMAIL_CAMPAIGN_2026_06_18_06_40&utm_medium=email&utm_term=0_-01baab3590-167840245
Strategic Prevention Framework - Partnerships for Success for Communities and Tribes (SPF-PFS Communities and Tribes)
Thursday, June 25, 2 p.m. ET
The purpose of the SPF-PFS Communities and Tribes grant program is to help prevent and reduce the initiation and progression of substance use and its related problems. The program intends to build prevention capacity throughout communities and tribes and to strengthen the capacity of local community prevention providers to implement evidence-based and evidence-informed prevention strategies.
https://events.gcc.teams.microsoft.com/event/f546ce5f-c27f-4a7c-ad79-b0813769a85c@d58addea-5053-4a80-8499-ba4d944910df?utm_source=SAMHSA&utm_campaign=01baab3590-EMAIL_CAMPAIGN_2026_06_18_06_40&utm_medium=email&utm_term=0_-01baab3590-167840245
Behavioral Health Partnerships for Early Diversion of Adults and Youth (Early Diversion)
Monday, June 29, 2 p.m. ET
The purpose of this program is to develop and implement a program to divert youth and/or adults with mental health or co-occurring disorders who are at risk of criminal and/or juvenile justice involvement to community-based services before arrest or booking. Working with community partners, the program identifies where help is needed to provide early diversion services to stabilize the individual. Services could include outreach, screening, crisis evaluation, brief counseling or support, and connecting the person to longer-term care in the community.
https://events.gcc.teams.microsoft.com/event/fd7b890c-cb86-4637-b341-5ea8fda001bf@d58addea-5053-4a80-8499-ba4d944910df?utm_source=SAMHSA&utm_campaign=01baab3590-EMAIL_CAMPAIGN_2026_06_18_06_40&utm_medium=email&utm_term=0_-01baab3590-167840245
“My pain is barely a comma now” June 16, 2026 Jesus Flores Writer and Editor, VISN 19 Creative Task Force ++ ++
https://news.va.gov/147466/my-pain-is-barely-a-comma-now/?utm_medium=email&utm_source=govdelivery
“My pain is no longer the period at the end of a sentence"
Army Veteran Dominic Sansone found it tough to get the pain relief he needed. The Cheyenne VA helped him focus on his whole health — sleep, movement, mood, nutrition, and daily routines. "The pain is still there, but I have the tools to accept and mitigate the impact pain has on my life.”
How Veterans help shape the future of MVP research
June 18, 2026
https://news.va.gov/147482/veterans-help-shape-future-mvp-research/?utm_medium=email&utm_source=govdelivery
Jennifer Deen
Associate Director, Cohort and Public Relations, Million Veteran Program
Setting the record straight: Your role in MVP research is more than a blood sample
Veterans enrolled in the Million Veteran Program (MVP) are helping advance research that may improve healthcare for Veterans nationwide. As research continues to grow, MVP remains committed to providing clear, accurate information about how participation in MVP contributes to scientific discoveries and future care. Here are a few important things to know.
Addressing homelessness among aging Veterans
June 17, 2026
https://news.va.gov/147477/addressing-homelessness-among-aging-veterans/?utm_medium=email&utm_source=govdelivery
Meredith Malpass
HUD-VASH Regional Coordinator, VHA Homeless Programs Office
A coordinated response to support aging homeless Veterans
In fiscal year 2024, almost half of all Veterans enrolled in VA healthcare were 65 or older. By fiscal year 2035, the number of Veterans aged 85 and older is expected to increase by 66%. Within this broader population, a growing subset of aging Veterans is experiencing or facing homelessness—some for the first time in their lives—due to factors like rising housing costs, complex medical needs, income loss or lack of family support.
Helping Veterans in tough moments with their suicide prevention safety plan
June 13, 2026
https://news.va.gov/147407/helping-veterans-suicide-prevention-safety-plan/?utm_medium=email&utm_source=govdelivery
Katie Rotolo
Suicide Prevention Quality Assurance & Technical Assistance Officer, Office of Suicide Prevention
You can support a Veteran in your life by learning about their safety plan
You can play an important role in a Veteran’s life by helping them with a suicide prevention safety plan. If a Veteran you care about has made a suicide attempt, shared thoughts of suicide, has a mental health condition that increases suicide risk, or may be at risk for suicide due to other reasons, a safety plan is one of the best practices available for suicide prevention.
Central Vertigo: Identifying the Hidden Cause Norberto Alvarez, MD ++´++
https://reference.medscape.com/p11/central-vertigo-identifying-hidden-cause-2026a1000idi?ecd=wnl_critimg_260619_mscpref_etid8431269&uac=148436CN&impID=8431269
Vertigo is an exaggerated or erroneous feeling of internal or external movement. The patient feels that they, or their environment, is moving or spinning.
Metastatic Breast Cancer: Current and Emerging Treatments
Shimoli Barot, MD
https://reference.medscape.com/p11/metastatic-breast-cancer-current-and-emerging-treatments-2026a1000hvf?ecd=wnl_critimg_260619_mscpref_etid8431269&uac=148436CN&impID=8431269
Breast cancer is the most common form of cancer in the United States, with an estimated 321,910 new cases (accounting for about 15% of all new female cancer cases) and 42,140 deaths in 2026. There are more than 4 million women living with breast cancer in the US, and 13.1% of US women will be diagnosed with breast cancer during their life.
Dermatologic Signs of Nutritional Deficiencies
Khaled El-Shazly, BSc; Lynne J. Goebel, MD, FACP
https://reference.medscape.com/p11/dermatologic-signs-nutritional-deficiencies-2026a1000glw?ecd=wnl_critimg_260619_mscpref_etid8431269&uac=148436CN&impID=8431269
The upcoming slides provide detailed guidance for performing medical examinations. Please be aware that these slides contain sensitive images intended as educational material for medical professionals.
Valvular Heart Disease
Yasmine S. Ali, MD, MSci
https://reference.medscape.com/p11/valvular-heart-disease-2026a1000fhu?ecd=wnl_critimg_260619_mscpref_etid8431269&uac=148436CN&impID=8431269
Calcific aortic stenosis is the dominant cause of valvular aortic stenosis in older adults in high-income settings, while bicuspid aortic valve disease remains an important cause of earlier-onset disease.[1,2] The prevalence of calcific aortic stenosis increases with age.[2,3] Other etiologies include congenital bicuspid aortic valve and rheumatic heart disease, with degenerative calcific aortic stenosis being most common in high-income countries.
jueves, 18 de junio de 2026
Remedi4all Hackathon - THE EUROPEAN PLATFORM FOR MEDICINES REPURPOSING
https://remedi4all.org/resources/remedi4all-repurposing-academy/remedi4all-hackathon/
REMEDi4ALL, a drug repurposing initiative in which EURORDIS is a partner, is accepting applications for its 2026 Hackathon. Designed for early-career researchers, the week-long programme offers hands-on experience in drug repurposing through multidisciplinary teamwork, expert guidance and collaboration with patient experts. Participants will work on real-world challenges while developing the skills needed to bring repurposed treatments closer to patients.
https://remedi4all.org/
Patient Partnership Webinar Series: Transition in Healthcare May 2026
https://www.eurordis.org/patient-partnership-webinar-series/
Join our new Patient Partnership webinar series, Transition in Healthcare: Turning Recommendations into Practice, on translating ERN recommendations for the transition from paediatric to adult healthcare into practice. The first webinar, on 30 June, will focus on implementation across healthcare systems, while the second, on 1 July, will showcase ERN tools and initiatives supporting effective transitions for people living with rare diseases.
Webinar #1: Setting the scene: From evidence to implementation in transition in healthcare
🗓️ Date: 30 June 2026
⏰ Time: 12:00-13:30 CEST
Webinar #2: ERN innovative initiatives – Developing tools and resources for an effective transition
🗓️ Date: 1 July 2026
⏰ Time: 12:00-13:15 CEST
Highlights from Prague: ECRD 2026 sets the course for coordinated action June 2026
https://www.eurordis.org/highlights-from-ecrd-2026/
Our 13th European Conference on Rare Diseases & Orphan Products (ECRD 2026) has concluded after two days of landmark discussions and strong political momentum. Held under the theme Rare Diseases in a Changing and Competitive Europe, the conference brought together patients, policymakers, healthcare professionals, researchers and industry – online and in Prague on 3–4 June – around a single, urgent message: Europe needs a coordinated, comprehensive EU Action Plan on Rare Diseases, and the time to act is now.
Practical solutions for real challenges: our ECRD 2026 Poster Pitch winners June 2026
https://www.eurordis.org/ecrd-2026-poster-pitch-winners/
ECRD 2026 showcased hundreds of posters mapping the challenges facing the rare disease community and the practical solutions being developed by those closest to them.
https://www.rare-diseases.eu/posters/
During the conference, our two Poster Pitch sessions invited top-scoring authors to present their work live. The winners, Romain Alderweireldt and Carlotta Emili, explored two very different challenges: Romain’s poster showed how patient-led data sharing could help researchers find answers in Marfan syndrome, while Carlotta’s examined how ultra-rare gene therapies can remain available when standard pricing models fall short.
AI tool could speed antibiotic development
https://www.nih.gov/news-events/nih-research-matters/ai-tool-could-speed-antibiotic-development
At a Glance
Researchers developed and tested a system to improve the antibacterial effects of existing compounds.
This system could help quickly create new antibiotics to overcome antibiotic resistance.
Depression screening using video games
https://www.nih.gov/news-events/nih-research-matters/researchers-test-video-game-diagnostic-depression
At a Glance
A study suggests that the unconscious way the brain assesses rewarding experiences is miscalibrated in patients with depression.
Game-like tasks to measure this mechanism could help doctors screen patients more quickly for depression.
Immune system may attack nervous system in some Long COVID patients
https://www.nih.gov/news-events/nih-research-matters/immune-system-may-attack-nervous-system-some-long-covid-patients
At a Glance
Researchers linked antibodies that attack the body’s nervous system to some neurological symptoms of Long COVID.
The results may point to possible treatments for some people with Long COVID.
New single-cell tool shows why antibody-based drugs fail The novel platform, called single-cell spatial pharmacobiology, revealed new insights into drug delivery of an antibody in Phase 1 trials. Written byAllison Whitten, PhD
https://www.drugdiscoverynews.com/new-single-cell-tool-shows-why-antibody-based-drugs-fail-17268
When a drug fails, it’s easy to assume that it was the wrong target or formulation or the side effects were too toxic. But it could also be that not enough of the drug got to its intended destination in the first place.
Super-potent synthetic opioids called nitazenes are spreading across the U.S. Up to 40 times stronger than fentanyl, nitazenes are often laced into other drugs
https://www.statnews.com/2026/06/18/nitazenes-deadly-synthetic-opioids-rapid-spread-united-states/
By Jonathan Moens — BellingcatJune 18, 2026
STAT is co-publishing this article with open-source investigative outlet Bellingcat.
New infant botulism outbreak puts fancy formulas under scrutiny Food safety experts say high-end formulas are not necessarily safer than other brands
https://www.statnews.com/2026/06/18/byheart-nara-botulism-outbreaks-premium-baby-formula-safety/
By Sarah ToddJune 18, 2026
Reporter, Commercial Determinants of Health
Data Updates Shift Treatment Standards in Gyn-Oncology Susana Campos, MD
https://www.medscape.com/viewarticle/data-updates-shift-treatment-standards-gyn-oncology-2026a1000k5c
Good morning, everyone. My name is Susana Campos. I’m a medical oncologist at Dana-Farber Cancer Institute. Thank you for joining me today. Over the next 20 minutes, we will review the most important gynecological oncology updates from ASCO 2026. Today’s topics span three disease areas: endometrial cancer, ovarian cancer, and cervical cancer.
What Space Travel Teaches Us About Cancer Biology David Kerr, MD, DSc
https://www.medscape.com/viewarticle/what-space-travel-teaches-us-about-cancer-biology-2026a1000j4e
Hello. I’m David Kerr, professor of cancer medicine at University of Oxford. There’s a fascinating article that’s just been published in The Lancet Oncology by the Stanford Stem Cell Research Group, looking at the potential terrestrial benefits of research in space.
Rare but Severe: Two Cases of Air Embolism After Lung Biopsy Anna Lynn Schreiber
https://www.medscape.com/viewarticle/rare-severe-two-cases-air-embolism-after-lung-biopsy-2026a1000kko
CT-guided percutaneous transthoracic lung biopsy has become an indispensable diagnostic tool for evaluating unclear pulmonary lesions. Although it is generally considered safe, it also carries risks — including systemic arterial air embolism.
Clinical Utility of Fast Comprehensive Genomic Profiling (CGP) in Solid Tumours
https://www.medscape.com/medicalaffairs/443484.2/media-1
Biomarker testing is the cornerstone of precision oncology, allowing patients to get access to biomarker-associated therapies. In this video, Dr Nicola Normanno discusses the importance of biomarker testing, focusing on comprehensive genomic profiling (CGP) for patients with solid tumours.
This resource explores the current clinical guidelines on the use of next-generation sequencing (NGS) and key real-world insights on the use of CGP in patients with advanced solid tumours.
Additionally, Dr Normanno outlines the performance of CGP in clinical practice, highlighting the impact of fast turnaround times. In which clinical scenarios does CGP bring value to clinical decision-making? Watch this video to find out.
Digital demands for chronic disease research and management The Lancet Digital Health ++... ++
Digital demands for chronic disease research and management
The Lancet Digital Health
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00064-6/fulltext?dgcid=raven_jbs_etoc_email
May 2026
Volume 8Number 5
https://www.thelancet.com/journals/landig/issue/vol8no5/PIIS2589-7500(26)X2005-2
Deep learning for H&E-based meningioma molecular classification and outcome prediction: a retrospective cohort study
Alexander P Landry, MDa,b,c,∗ ∙ Farshad Nassiri, MD PhDa,b,c,∗ ∙ Leeor S Yefet, MDa,b,c ∙ H Lalchungnunga, PhDd ∙ Eldad D Shulman, PhDd ∙ Justin Z Wang, MDa,b,c ∙ et al.
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00009-9/fulltext?dgcid=raven_jbs_etoc_feature_landig
Detection of young-onset type 2 diabetes using deep learning across primary and secondary care: a nationwide, retrospective cohort study
Christian Holm Johansen, MSca,b,c ∙ Jessica Xin Hjaltelin, PhDa,b,c ∙ Davide Placido, PhDa ∙ Samuel Cadell, BSca,b ∙ Prof Laust Hvas Mortensen, PhDb,c ∙ Prof Frans Boch Waldorff, MDb ∙ et al.
https://www.thelancet.com/journals/landig/article/PIIS2589-7500(25)00150-5/fulltext?dgcid=raven_jbs_etoc_feature_landig
Lessons Learned from our Roundtable with Rare Disease Advocates
https://www.fda.gov/news-events/fda-voices/lessons-learned-our-roundtable-rare-disease-advocates?utm_medium=email&utm_source=govdelivery
Lessons Learned from our Roundtable with Rare Disease Advocates
There is no substitute for sitting across the table from the people we serve. Recently we had the privilege of joining Acting Commissioner Kyle Diamantas, Acting Chief of Staff Lowell Zeta, and Deputy Commissioner Grace Graham for a roundtable discussion with 15 dedicated rare disease leaders. Hearing directly from patients and family members who navigate these incredibly challenging conditions every day was both grounding and motivating. The conversation reinforced our shared mission and highlighted several key areas where the U.S. Food and Drug Administration must continue to evolve to meet the unique needs of the rare disease community.
During the discussion, we emphasized the FDA’s renewed unwavering commitment to the rare disease community. We made it clear that our medical product decisions must always be rooted in rigorous science and driven by the deep expertise of the FDA’s outstanding scientists and reviewers. While leadership sets the strategic vision, the real engine of this work is our incredibly hard-working career scientists across our medical product centers. Their dedication to evaluating complex data under intense timelines is what transforms scientific possibility into real-world hope for patients.
miércoles, 17 de junio de 2026
Medical Treatment and Stem-Cell Transplantation in Patients With Cutaneous T-Cell Lymphoma by CheckRare Staff| Published on: Jun 17, 2026
Medical Treatment and Stem-Cell Transplantation in Patients With Cutaneous T-Cell Lymphoma
by CheckRare Staff| Published on: Jun 17, 2026
Lauren Shea, MD, Assistant Professor of Hematology and Oncology, University of Alabama, Birmingham, discusses important aspects of medical treatment and stem-cell transplantation in patients with cutaneous T-cell lymphoma (CTCL).
https://checkrare.com/medical-treatment-and-stem-cell-transplantation-in-patients-with-cutaneous-t-cell-lymphoma/
Suscribirse a:
Entradas (Atom)
.png)
